FDA Drug Safety Podcast: FDA requires drug interaction studies with potassium-lowering drug Kayexalate (sodium polystyrene sulfonate)

On October 22, 2015, the FDA announced it is requiring the Kayexalate manufacturer to conduct studies to investigate Kayexalate’s potential to bind to other medications administered by mouth – drug interactions that could affect how well the other medications work.
Source: FDA Drug Safety Podcasts